Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2009

01-05-2009 | Original Article

Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer

Authors: Masaru Nakamura, Tomonobu Koizumi, Munehara Hayasaka, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Kotaro Gomi, Naoto Shikama

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2009

Login to get access

Abstract

Purpose

Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).

Methods

A total of 34 patients aged less than 75 years old with locally advanced stage III NSCLC were enrolled. The patients received intravenous infusions of cisplatin (80 mg/m2; day 1) and docetaxel (20 mg/m2; days 1, 8, 15), followed by a week’s drug-free interval. Standard concurrent thoracic radiotherapy was given for 6 weeks (2 Gy per fraction; total dose, 60 Gy).

Results

Over Grade 3 neutropenia, esophagitis and pulmonary toxicities were observed in 23.5, 17.6 and 11.8% of the cases, respectively. One complete response and 20 partial responses were obtained, with an objective response rate of 61.8%. The median survival time was 26.4 months (95% CI 16.9—not reached) and the 1- and 3-year survival rates were 76.5 and 41.2%, respectively.

Conclusion

Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.
Literature
1.
Dillman RO, Herndon J, Seagren SL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210–1215PubMedCrossRef
2.
Sause W, Kolesar P, Taylor SIV et al (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358–364PubMedCrossRef
3.
Belani CP, Choy H, Bonomi P et al (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883–5891PubMedCrossRef
4.
Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMed
5.
Curran D, Scott C, Langer C et al (2003) Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiotherapy for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621
6.
Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95–01 Study. J Clin Oncol 23:5910–5917PubMedCrossRef
7.
Kunitoh H, Watanabe K, Furuse K et al (1996) Phase II trial of Decetaxel in previously untreated advanced non-small–cell lung cancer: a Japanese Cooperative study. J Clin Oncol 14:1649–1655PubMed
8.
Schiller JH, Harrington D, Belani CP et al (2002) Eastern Cooperative Oncology Group. For the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef
9.
Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254–261PubMedCrossRef
10.
Choy H, Rodriguez S, Koester S et al (1993) Synergic effects of Taxol/Taxotere on radiation sensitivity on human tumor cell lines. Int J Radiat Oncol Biol Phys 24:274–275
11.
Mason KA, Hunter NR, Milas M et al (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3(12 Pt 1):2431–2438PubMed
12.
Karasawa K, Katsui K, Seki K et al (2003) Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 10:268–274PubMedCrossRef
13.
Koukourakis MI, Kourousis C, Kamilaki M et al (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation. Eur J Cancer 34:838–844PubMedCrossRef
14.
Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no gut survival due to radiation pneumonitis. Lung Cancer 40:79–84PubMedCrossRef
15.
Koizumi T, Tsunoda T, Fujimoto K et al (2001) Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small-cell lung cancer. Lung Cancer 34:125–131PubMedCrossRef
16.
Tsunoda T, Koizumi T, Hayasaka M et al (2004) Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 54:173–177PubMedCrossRef
17.
Alvarez MV, Cobreros G, Heras A et al (1978) Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer. Br J Cancer 3:68–72
18.
Dewit L (1987) Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403–426PubMed
19.
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
20.
21.
Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef
22.
Yamamoto N, Nishimura Y, Nakagawa K et al (2006) Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol 58:285–291PubMedCrossRef
23.
Wu HG, Bang YJ, Choi EK et al (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:75–80PubMed
24.
Mudad R, Ramsey M, Kovitz K et al (2003) Concomitant weekly docetaxel, cisplatin and radiotherapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39:173–177PubMedCrossRef
25.
Kiura K, Ueoka H, Segawa Y et al (2003) Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89:795–802PubMedCrossRef
26.
Iwasaki Y, Ohsugi S, Natsuhara A et al (2006) Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 58:735–741PubMedCrossRef
27.
Albain KS, Crowley JJ, Turrisi AT 3rd et al (2002) A Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454–3460PubMedCrossRef
28.
Robert F, Spencer SA, Childs HA 3rd et al (2002) Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer 37:189–199PubMedCrossRef
29.
Hainsworth JD, Burris HA 3rd, Erland JB et al (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164–2168PubMed
30.
Ohe Y, Niho S, Kakinuma R et al (2001) Phase I studies of cisplatin and docetaxel administration by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol 31:100–106PubMedCrossRef
31.
Socinski MA, Zhang C, Herndon JE 2nd et al (2004) Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15:1033–1041PubMedCrossRef
32.
Hirose T, Mizutani Y, Ohmori T et al (2006) The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Cancer Chemother Pharmacol 58:361–367PubMedCrossRef
33.
Sakai H, Yoneda S, Kobayashi K et al (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43:195–201PubMedCrossRef
Metadata
Title
Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer
Authors
Masaru Nakamura
Tomonobu Koizumi
Munehara Hayasaka
Masanori Yasuo
Kenji Tsushima
Keishi Kubo
Kotaro Gomi
Naoto Shikama
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0837-0

Other articles of this Issue 6/2009

Cancer Chemotherapy and Pharmacology 6/2009 Go to the issue

Original Article

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors

Original Article

Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression

Original Article

Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer

Original Article

Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells

Original Article

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Short Communication

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits